​

Avalo Therapeutics Ownership | Who Owns Avalo Therapeutics?

OverviewRevenueFinancialsChart

Avalo Therapeutics Ownership Summary

Avalo Therapeutics is owned by 78.51% institutional investors, 6.39% insiders, and 15.10% retail investors. Vanguard Institutional Extnd Mkt Idx Tr is the top mutual fund, with 1.53% of its assets in Avalo Therapeutics shares.

AVTX Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockAvalo Therapeutics78.51%6.39%15.10%
SectorHealthcare Stocks 279.19%10.58%-189.76%
IndustryBiotech Stocks 63.97%10.68%25.35%

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Mar 31, 202533-8,255,0579.62%781.52%15-11.76%433.33%
Dec 31, 20243317.86%7,530,52113.12%711.07%1730.77%3200.00%
Sep 30, 20242833.33%6,656,933763.30%8191.00%1318.18%1-75.00%
Jun 30, 20242116.67%771,102781.19%9818.57%11-4-
Mar 31, 20241850.00%87,507281.03%11348.78%11175.00%4-50.00%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
Vanguard Institutional Extnd Mkt Idx Tr165.80K1.53%-
Fidelity Extended Market Index52.93K0.50%1.66K
Extended Equity Market Fund K19.53K0.18%60.00
Fidelity Total Market Index18.63K0.17%-2.83K
Fidelity Series Total Market Index13.40K0.13%-
NT Ext Equity Mkt Idx Fd - NL11.56K0.11%-
NT Ext Equity Mkt Idx Fd - L10.61K0.10%-
Northern Trust Extended Eq Market Idx10.61K0.10%-
Spartan Extended Market Index Pool E10.27K0.10%3.89K
Spartan Extended Market Index Pool F10.27K0.09%3.89K

Recent Insider Transactions

DateNameRoleActivityValue
Nov 13, 2024Almenoff June Sherie-Buy$6.50K
Nov 12, 2024Almenoff June Sherie-Buy$6.25K
Jun 26, 2023ARMISTICE CAPITAL, LLC-Sell$1.68M
Jun 27, 2023ARMISTICE CAPITAL, LLC-Sell$486.89K
Jun 26, 2023Caissa Capital Management ltd.-Sell$113.03K

Insider Transactions Trends

DateBuySell
2025 Q1--
2024 Q42-
2024 Q3--
2024 Q2--
2024 Q1--

AVTX Ownership FAQ

Who Owns Avalo Therapeutics?

Avalo Therapeutics shareholders are primarily institutional investors at 78.51%, followed by 6.39% insiders and 15.10% retail investors. The average institutional ownership in Avalo Therapeutics's industry, Biotech Stocks , is 63.97%, which Avalo Therapeutics exceeds.

Does Blackrock own Avalo Therapeutics?

BlackRock is not among the top 10 institutional shareholders of Avalo Therapeutics.

Who is the top mutual fund holder of Avalo Therapeutics shares?

Vanguard Institutional Extnd Mkt Idx Tr is the top mutual fund holder of Avalo Therapeutics shares, with 1.53% of its total shares outstanding invested in 165.8K Avalo Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools